Others in the FDA queue include Bausch’s psoriasis therapy Duobrii and Motif Bio’s antibiotic Iclaprim.
Ascendis aims to hit the Heights, while Lilly hopes for success with Olumiant in eczema, a new indication for the troubled Jak inhibitor.
Allergan needs a win with rapastinel, while Lundbeck's chief exec faces her second clinical challenge.
Allergy Therapeutics awaits twice-delayed phase III data on its birch pollen project, while Caladrius Biosciences seeks validation of its Treg approach to type 1…
Jazz wants to expand its sleep portfolio, while Macrogenics hopes trial data will support its first new drug application.
Novavax awaits phase III data with its respiratory syncytial virus vaccine ResVax, while Mallinckrodt hopes to bounce back with its next big pipeline hope, CPP-1X plus…
Shutdown or no, drug reviews are still under way, giving the sector something to look forward to as 2019 kicks off.
Urogen is gearing up to release the results of a pivotal trial of its lead asset – and so is Mediwound.
Verona Pharma needs another COPD win, while Alexion seeks a new use for its Soliris successor.